Symptoms and Management Strategies in Gastroesophageal Reflux Disease (GERD) (PHENIX)

AstraZeneca

Status: Completed

Conditions: Gastroesophageal Reflux Disease

Study type: Observational

Funder types: Industry

Identifiers

NCT00768443

NIS-GHR-NEX-2008/1

Details and patient eligibility

About

This a non-interventional multi-centre study to evaluate the symptom load and management strategies in PPI-treated GERD patients with persistent GERD symptoms..

Enrollment: 2,674 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Provision of informed consent
• Subjects with a diagnosis of GERD and with predominant typical GERD symptoms: heartburn/regurgitation
• Subjects who fail to obtain satisfactory symptomatic response after their first full course (4-8 weeks) of standard dose PPI (once a day)

Exclusion criteria

• Inability to read and/or understand Patient Reported Outcomes questionnaires
• Subjects where the only reason for the visit is renewing the prescription
• A history of an incomplete response to PPI treatment prior to current course of treatment